Williams Thomas J, Hlaing Phyu, Maher Adrian M, Walker Neal, Kendall Bradley J, Holtmann Gerald, Hourigan Luke F
Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Australia.
School of Medicine, University of Queensland, Brisbane, Australia.
J Clin Gastroenterol. 2025 Apr 1;59(4):321-324. doi: 10.1097/MCG.0000000000002026.
Endoscopic mucosal resection (EMR) is an established technique for the diagnosis and treatment of high-grade dysplasia (HGD) and early esophageal adenocarcinoma (EAC) in Barrett's esophagus. Submucosal preinjection is not universally used or generally recommended when performing routine ligation-assisted EMR. Prior studies, however, have demonstrated evidence of at least superficial muscle injury on ligation-assisted EMR without submucosal injection. There are limited published data supporting any potential benefit of submucosal preinjection. Our aim was to review this technique and determine the rate of any degree of muscle injury in patients with Barrett's HGD and EAC treated with submucosal preinjection before ligation-assisted EMR.
Patients undergoing submucosal preinjection before ligation-assisted EMR for Barrett's esophagus at a single institution between 2012 and 2016 were identified. Data were collected regarding patient demographics and medical history, endoscopy and histopathology findings, adverse events, and subsequent outcomes. All EMR specimens were reviewed by an expert gastrointestinal pathologist.
One hundred fifty consecutive EMR procedures were performed on 70 patients. Of 70 patients, 85.7% of patients were men, with a median age of 68 years. EAC was identified in 75 specimens (50%) and HGD in 44 specimens (29.3%). Deep resection margins were clear of adenocarcinoma in all specimens. Muscularis propria was not identified in any of the 150 specimens. There were no cases of post-EMR perforation.
Preinjection before ligation-assisted EMR achieved complete excision with histologically clear margins, without histological evidence of any inadvertent muscularis propria.
内镜黏膜切除术(EMR)是诊断和治疗巴雷特食管高级别上皮内瘤变(HGD)及早期食管腺癌(EAC)的成熟技术。在进行常规套扎辅助EMR时,黏膜下预注射并非普遍使用或被推荐。然而,既往研究表明,在未进行黏膜下注射的套扎辅助EMR中,至少存在浅表肌层损伤的证据。支持黏膜下预注射潜在益处的已发表数据有限。我们的目的是回顾该技术,并确定在套扎辅助EMR前进行黏膜下预注射治疗的巴雷特HGD和EAC患者中任何程度肌层损伤的发生率。
确定2012年至2016年在单一机构接受套扎辅助EMR前黏膜下预注射治疗巴雷特食管的患者。收集有关患者人口统计学和病史、内镜及组织病理学检查结果、不良事件及后续结局的数据。所有EMR标本均由一位胃肠病学专家病理学家进行评估。
对70例患者连续进行了150次EMR手术。70例患者中,85.7%为男性,中位年龄为68岁。75份标本(50%)确诊为EAC,44份标本(29.3%)为HGD。所有标本的深层切除边缘均无腺癌。150份标本中均未发现固有肌层。无EMR术后穿孔病例。
套扎辅助EMR前预注射可实现组织学切缘清晰的完整切除,且无任何意外固有肌层的组织学证据。